Sunitinib in Treating Patients With Relapsed Multiple Myeloma
NCT00514137
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
13
Enrollment
NIH
Sponsor class
Conditions
Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Interventions
DRUG:
sunitinib malate
Sponsor
National Cancer Institute (NCI)